February 2015

Originally published in the Wall Street Journal by Editorial Staff It should not go unnoticed that last week the Food and Drug Administration announced it would “simplify and accelerate” the application process for “unapproved investigational drugs” that have passed Phase I safety trials. We are back on the most contentious ground of FDA drug approval, […]

Originally published in USA Today A person with a terminal illness may hear of a drug that could be promising only to hear it has not yet received government approval for use. Unless that person can find his or her way into a clinical trial for that compound, he or she will most likely not […]